Related Experiment Video
Updated: Aug 11, 2026
Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
[Use of WOBE-MUGOS E for prevention and correction of experimental doxorubicin side-effects]
Abstract:
Examined in treating rats with Guerin's carcinoma with doxorubicin was the possibility that the polyenzymic drug preparation wobe-mugos E had hepatoprotective, cardioprotective and myeloprotective effects. In intramuscular administration wobe-mugos E has not been found to stimulate the tumour growth, it exhibited a manifest hepatoprotective and myeloprotective actions with respect to adverse reactions of doxorubicin but failed to diminish cardiotoxicity of the latter. The protective effect of the above polyenzymic drug was of a dose-dependent character.
Insights
The polyenzymic drug wobe-mugos E demonstrated hepatoprotective and myeloprotective effects in rats treated with doxorubicin. However, it did not reduce doxorubicin-induced cardiotoxicity, with effects being dose-dependent.
Area of Science:
- Pharmacology
- Oncology
- Biochemistry
Context:
- Doxorubicin is a potent chemotherapy agent with significant toxic side effects.
- Assessing protective agents against chemotherapy-induced toxicity is crucial for improving patient outcomes.
- Guerin's carcinoma in rats serves as a model for evaluating anti-cancer drug effects and toxicities.
Purpose:
- To investigate the potential hepatoprotective, cardioprotective, and myeloprotective effects of wobe-mugos E.
- To determine if wobe-mugos E influences tumor growth when co-administered with doxorubicin.
- To establish the dose-dependency of wobe-mugos E's protective actions.
Summary:
- Wobe-mugos E, a polyenzymic preparation, was administered to rats with Guerin's carcinoma undergoing doxorubicin treatment.
- Intramuscular administration of wobe-mugos E did not stimulate tumor growth.
- The drug exhibited significant hepatoprotective and myeloprotective effects against doxorubicin's adverse reactions but did not mitigate cardiotoxicity.
Impact:
- Wobe-mugos E shows promise in managing specific doxorubicin-induced toxicities, particularly liver and bone marrow.
- The lack of cardiotoxicity mitigation highlights the need for further research into combined doxorubicin and wobe-mugos E therapy.
- Findings suggest a potential role for wobe-mugos E as an adjunct therapy, with its efficacy dependent on dosage.
